The Future Direction of Cancer Vaccines: An Editorial
DOI:
https://doi.org/10.17140/VROJ-6-e007Abstract
In the past, vaccines were defined as prophylactic entities. Today, there are two types of vaccines: prophylactic for prevention, and
therapeutic for the treatment of infections or cancers. Therapeutic cancer vaccine, in fact, represents an option for active immunotherapy for the treatment of late-stage and/or prevention of recurrent diseases.1 The function of a therapeutic cancer vaccine in patients is the eradication of cancer cells by strengthening the patient’s own immune response.2 This type of immunotherapy not only provides a new modality for cancer treatment but also paves the way for designing various therapeutic vaccines for chronic infections. 3
In spite of vast progress in this pathway, developing effective and safe therapeutic vaccines is still in its infancy when compared with prophylactic vaccines and immunotherapeutic agents.4 Before new technologies were applied for developing therapeutic vaccines, a few of them like bacilli galmette-guerrin (BCG) was used for the treatment of bladder, and prostate cancers.5,6 Recently, it has been reported successful use of the human papilloma virus (HPV) vaccine for the treatment of multiple cutaneous malignancies. 7
References
Patil SU, Schreffler WG. Novel vaccine: Technology and devel-opment. J Arllergy Clin Immunol. 2019; 143: 844-851. doi: 10.1016/j. jaci.2018.05.021
Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumor pre-vention. Nat Rev Cancer. 2006; 6: 204-216. doi: 10.1038/nrc1815 e1 Vaccin Res Open J. 2022; 6(1): e1-e2. doi: 10.17140/VROJ-6-e007
Boukhebza H, Bellon N, Linhacher JC, Inchauspe N. Thera-peutic vaccination to treat chronic infectious diseases. Hum Vaccin Immunother. 2012; 8: 1746-1757. doi: 10.4161/hv.21689
Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: Past, present and future. Adv Cancer Res. 2013; 119: 421-475. doi: 10.1016/B978-0-12-407190-2.00007-1
Vandeborne L, Pantziarka P, van Nuffel AMT, Bouche G. Re-purposing infectious disease vaccines against cancer. Front Oncol. 2021; 11: 688755. doi: 10.3389/fonc.2021.688755
Morales A. Adjuvant immunotherapy in superficial bladder can-cer. Natl Cancer Inst Monogr. 1978; 49: 315-319.
Geizhals S, Lebwol MG. Successful treatment of multiple cu-taneous malignancies with HPV vaccination. Case report. SKIN The Journal of Cutaneous Medicine. 2020; 4: 148-155. doi: 10.25251/ skin.4.2.9
Khansari N. Dendritic cell vaccine and its application in can-cer therapy. Int J Vaccines Vaccin. 2015; 1: 1-5. doi: 10.15406/ ijvv.2015.01.00002
Smith AJ, Oertle J, Warren D, Prato D. Chimeric antigen re-ceptor (CAR) T cell therapy for malignant cancers: Summary and perspective. J Cell Immunother. 2016; 6: 59-68. doi: 10.1016/j.joc-it.2016.08.001
Kailshiya C, Sharma HB, Kailshiya J. Telomerase based anti-cancer immunotherapy and vaccines approaches. Vaccine. 2017; 35: 5768-5775. doi: 10.1016/j.vaccine.2017.09.011
Liu MA. DNA vaccines: An historical perspective and view to the future. Immunol Rev. 2011; 239: 62-84. doi: 10.1111/j.1600- 065X.2010.00980.x
Farashi-Bonab S, Khansari N. Improving clinical efficacy of cancer vaccine using neoantigen identified in cancer patients. Vac-cine & Vaccination Res. 2019; 4: 20-27. Submit your article to this journal | https://openventio.org/submit-manuscript/ e2 Khansari N
Jain S, Venhataraman A, Wechsler ME, Peppad NA. Messen-ger RNA-based vaccines: Past, present, and future in the context of Covid-19 pandemic. Adv Drug Deliv Rev. 2021; 179: 14000. doi: 10.1016/j.addr.2021.114000
Kasherman L, Ahrari S, Lheureux S. Dostarlimab in the treat-ment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021; 17: 877-892. doi: 10.2217/fon-2020-0655
Redman JM, Gibney GT, Atkine MB. Advances in immuno-therapy for melanoma. BCM Med. 2016; 14: 20-31. doi: 10.1186/ s12916-016-0571-0
Keating GM. Panitumumab: A review of its use in meta-static colorectal cancer. Drugs. 2010; 28: 1059-1078. doi: 10.2165/11205090-000000000-00000
Greg LB, Figgitt DP. Rituximab. Drugs. 2012; 63: 803-843.
McKeage K, Pery CM. Trastuzumab: A review of its use in treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002; 62: 209-243.
Galizia G, Lieto E, De vita F, et al. Cetuximab, a chimeric hu-man mouse anti-epidermal growth factor receptor monoclonal an-tibody, in the treatment of human colorectal cancer. Oncogene. 2007; 26: 3654-3660. doi: 10.1038/sj.onc.1210381
Kazazi-Hyseni F, Beijnen JH, Schellens JHM. Bevacizumab. On-cologist. 2010; 15: 819-820. doi: 10.1634/theoncologist.2009-0317
Cordo V, Van der Zwet JC, Cante-Barrett K, Pieters R, Meijer-ink JP. T- cell acute lymphoblastic leukemia: A road map to target-ed therapies. Blood Cancer Discov. 2021; 2: 19-31. doi: 10.1158/2643- 3230.BCD-20-0093
Broccoli A, Argnani L, Zinzani PL. Peripheral T-cell lympho-ma. Focus on novel agents in relapsed and refractory disease. Can-cer Treatment Rev. 2017; 60: 120-129. doi: 10.1016/j.ctrv.2017.09.002 Editorial | Volume 6 | Number 1|
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.